(Q37301003)

19 August 2017

1 reference

title

Melanoma genetics and therapeutic approaches in the 21st century: moving from the benchside to the bedside (English)

1 reference

19 August 2017

Thomas L Hocker

1

1 reference

19 August 2017

Meena K Singh

series ordinal

2

1 reference

19 August 2017

Hensin Tsao

series ordinal

3

1 reference

19 August 2017

language of work or name

English

0 references

publication date

1 November 2008

1 reference

Journal of Investigative Dermatology

19 August 2017

1 reference

19 August 2017

128

1 reference

19 August 2017

2575-2595

1 reference

19 August 2017

11

1 reference

https://scigraph.springernature.com/pub.10.1038/jid.2008.226

19 August 2017

0 references

cites work

Metastasizing Melanoma Formation Caused by Expression of Activated N-RasQ61Kon an INK4a-Deficient Background

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.226

7 January 2021

The regulation of cyclin D1 degradation: roles in cancer development and the potential for therapeutic invention

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.226

7 January 2021

Transforming ras genes from human melanoma: a manifestation of tumour heterogeneity?

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.226

7 January 2021

Augmenting chemosensitivity of malignant melanoma tumors via proteasome inhibition: implication for bortezomib (VELCADE, PS-341) as a therapeutic agent for malignant melanoma

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.226

7 January 2021

Bcl-2 overexpression results in reciprocal downregulation of Bcl-X(L) and sensitizes human testicular germ cell tumours to chemotherapy-induced apoptosis

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.226

7 January 2021

Death receptors: signaling and modulation

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.226

7 January 2021

Reversal of methylation silencing of Apo2L/TRAIL receptor 1 (DR4) expression overcomes resistance of SK-MEL-3 and SK-MEL-28 melanoma cells to interferons (IFNs) or Apo2L/TRAIL.

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.226

7 January 2021

Cloning the chromosomal breakpoint of t(14;18) human lymphomas: clustering around JH on chromosome 14 and near a transcriptional unit on 18.

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.226

7 January 2021

Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.226

7 January 2021

Phase I pharmacokinetic and pharmacodynamic study of 17-allylamino, 17-demethoxygeldanamycin in patients with advanced malignancies

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.226

7 January 2021

Dual inactivation of RB and p53 pathways in RAS-induced melanomas

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.226

7 January 2021

Mutations and copy number increase of HRAS in Spitz nevi with distinctive histopathological features

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.226

7 January 2021

Congenital melanocytic nevi frequently harbor NRAS mutations but no BRAF mutations

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.226

7 January 2021

Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: the Oblimersen Melanoma Study Group

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.226

7 January 2021

Human melanocyte senescence and melanoma susceptibility genes

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.226

7 January 2021

DNA methylation patterns and epigenetic memory

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.226

7 January 2021

Valproate and valproate-analogues: potent tools to fight against cancer.

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.226

7 January 2021

Temozolomide in advanced malignant melanoma with small brain metastases: can we withhold cranial irradiation?

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.226

7 January 2021

Mutated N-ras upregulates Bcl-2 in human melanoma in vitro and in SCID mice

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.226

7 January 2021

Histone deacetylase inhibitors and malignant melanoma.

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.226

7 January 2021

Mitf cooperates with Rb1 and activates p21Cip1 expression to regulate cell cycle progression

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.226

7 January 2021

The gene encoding the T-box factor Tbx2 is a target for the microphthalmia-associated transcription factor in melanocytes

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.226

7 January 2021

Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.226

7 January 2021

BCL-2, BCL-X(L) sequester BH3 domain-only molecules preventing BAX- and BAK-mediated mitochondrial apoptosis

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.226

7 January 2021

Down-regulation of mcl-1 by small interfering RNA sensitizes resistant melanoma cells to fas-mediated apoptosis

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.226

7 January 2021

Cooperative effects of INK4a and ras in melanoma susceptibility in vivo

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.226

7 January 2021

Essential role for oncogenic Ras in tumour maintenance

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.226

7 January 2021

Cytogenetic analysis of melanocytes from premalignant nevi and melanomas

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.226

7 January 2021

DNA damage response and MCL-1 destruction initiate apoptosis in adenovirus-infected cells

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.226

7 January 2021

Somatic activation of KIT in distinct subtypes of melanoma

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.226

7 January 2021

Distinct sets of genetic alterations in melanoma

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.226

7 January 2021

PI3-kinase subunits are infrequent somatic targets in melanoma.

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.226

7 January 2021

Activated B-RAF is an Hsp90 client protein that is targeted by the anticancer drug 17-allylamino-17-demethoxygeldanamycin

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.226

7 January 2021

Therapeutic targets: MTOR and related pathways

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.226

7 January 2021

Cell death: critical control points

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.226

7 January 2021

Randomized phase II study of temozolomide given every 8 hours or daily with either interferon alfa-2b or thalidomide in metastatic malignant melanoma

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.226

7 January 2021

Mutations of the BRAF gene in human cancer

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.226

7 January 2021

Treatment of melanoma cells with a bcl-2/bcl-xL antisense oligonucleotide induces antiangiogenic activity

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.226

7 January 2021

Interleukin-3-induced phosphorylation of BAD through the protein kinase Akt

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.226

7 January 2021

Beta-catenin induces immortalization of melanocytes by suppressing p16INK4a expression and cooperates with N-Ras in melanoma development

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.226

7 January 2021

Control of neural crest cell fate by the Wnt signalling pathway.

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.226

7 January 2021

Randomized trial of treatment with cisplatin and interleukin-2 either alone or in combination with interferon-alpha-2a in patients with metastatic melanoma: a Federation Nationale des Centres de Lutte Contre le Cancer Multicenter, parallel study

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.226

7 January 2021

Palliative therapy of disseminated malignant melanoma: a systematic review of 41 randomised clinical trials.

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.226

7 January 2021

Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.226

7 January 2021

Differential regulation of noxa in normal melanocytes and melanoma cells by proteasome inhibition: therapeutic implications.

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.226

7 January 2021

Homozygous deletions within human chromosome band 9p21 in melanoma

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.226

7 January 2021

ABCB5-mediated doxorubicin transport and chemoresistance in human malignant melanoma

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.226

7 January 2021

Cell type specific involvement of death receptor and mitochondrial pathways in drug-induced apoptosis

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.226

7 January 2021

Mitochondria as therapeutic targets for cancer chemotherapy

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.226

7 January 2021

Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.226

7 January 2021

Activity of a novel bcl-2/bcl-xL-bispecific antisense oligonucleotide against tumors of diverse histologic origins.

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.226

7 January 2021

Mutation of the KIT (mast/stem cell growth factor receptor) protooncogene in human piebaldism

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.226

7 January 2021

Chemotherapy for metastatic melanoma: time for a change?

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.226

7 January 2021

Phase I trial of sequential low-dose 5-aza-2'-deoxycytidine plus high-dose intravenous bolus interleukin-2 in patients with melanoma or renal cell carcinoma.

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.226

7 January 2021

Overexpression of Akt converts radial growth melanoma to vertical growth melanoma.

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.226

7 January 2021

Melanoma biology and new targeted therapy

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.226

7 January 2021

V600E B-Raf requires the Hsp90 chaperone for stability and is degraded in response to Hsp90 inhibitors

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.226

7 January 2021

The discovery of receptor tyrosine kinases: targets for cancer therapy

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.226

7 January 2021

ARF functions as a melanoma tumor suppressor by inducing p53-independent senescence

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.226

7 January 2021

The mitogen-activated protein/extracellular signal-regulated kinase kinase inhibitor AZD6244 (ARRY-142886) induces growth arrest in melanoma cells and tumor regression when combined with docetaxel

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.226

7 January 2021

Bcl-XL is a chemoresistance factor in human melanoma cells that can be inhibited by antisense therapy

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.226

7 January 2021

Drug-resistance in human melanoma

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.226

7 January 2021

Regulation of the mitochondrial checkpoint in p53-mediated apoptosis confers resistance to cell death

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.226

7 January 2021

Gene silencing in cancer in association with promoter hypermethylation

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.226

7 January 2021

Current strategies in overcoming resistance of cancer cells to apoptosis melanoma as a model.

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.226

7 January 2021

Ultraviolet radiation and melanoma: a systematic review and analysis of reported sequence variants

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.226

7 January 2021

Mutations at the mouse microphthalmia locus are associated with defects in a gene encoding a novel basic-helix-loop-helix-zipper protein

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.226

7 January 2021

Death and anti-death: tumour resistance to apoptosis

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.226

7 January 2021

Ki-67, Bcl-2 and p53 expression in primary and metastatic melanoma.

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.226

7 January 2021

bcl-2 antisense therapy chemosensitizes human melanoma in SCID mice

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.226

7 January 2021

Chemosensitisation of malignant melanoma by BCL2 antisense therapy

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.226

7 January 2021

Cancer statistics, 2008

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.226

7 January 2021

Inhibition of MEK sensitizes human melanoma cells to endoplasmic reticulum stress-induced apoptosis

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.226

7 January 2021

N-ras mutations are common in melanomas from sun-exposed skin of humans but rare in mucosal membranes or unexposed skin

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.226

7 January 2021

A cell cycle regulator potentially involved in genesis of many tumor types

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.226

7 January 2021

Functional and physical interactions of the ARF tumor suppressor with p53 and Mdm2

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.226

7 January 2021

B-RAF is a therapeutic target in melanoma

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.226

7 January 2021

AKT/PKB signaling mechanisms in cancer and chemoresistance

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.226

7 January 2021

Comparative Oncogenomics Identifies NEDD9 as a Melanoma Metastasis Gene

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.226

7 January 2021

Apoptosis and melanogenesis in human melanoma cells induced by anthrax lethal factor inactivation of mitogen-activated protein kinase kinase

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.226

7 January 2021

Epigenetic silencing of multiple interferon pathway genes after cellular immortalization.

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.226

7 January 2021

Expression, purification, characterization and homology modeling of active Akt/PKB, a key enzyme involved in cell survival signaling

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.226

7 January 2021

MC1R germline variants confer risk for BRAF-mutant melanoma

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.226

7 January 2021

Antiapoptotic bcl-2 and bcl-xL in advanced malignant melanoma

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.226

7 January 2021

p53-dependent apoptosis in melanoma cells after treatment with camptothecin

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.226

7 January 2021

Chemotherapy-induced apoptosis in melanoma cells is p53 dependent.

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.226

7 January 2021

Analysis of BRAF mutation in primary and metastatic melanoma.

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.226

7 January 2021

Phase I and pharmacodynamic study of the oral MEK inhibitor CI-1040 in patients with advanced malignancies

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.226

7 January 2021

PRAS40 deregulates apoptosis in malignant melanoma

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.226

7 January 2021

Involvement of the pRb/p16/cdk4/cyclin D1 pathway in the tumorigenesis of sporadic malignant melanomas

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.226

7 January 2021

AKT/PKB signaling: navigating downstream

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.226

7 January 2021

CCI-779 in metastatic melanoma: a phase II trial of the California Cancer Consortium

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.226

7 January 2021

A phase II study of bortezomib in the treatment of metastatic malignant melanoma

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.226

7 January 2021

Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.226

7 January 2021

Bcl2 regulation by the melanocyte master regulator Mitf modulates lineage survival and melanoma cell viability

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.226

7 January 2021

The RAS/RAF/MEK/ERK and PI3K/AKT signaling pathways present molecular targets for the effective treatment of advanced melanoma

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.226

7 January 2021

Docetaxel-induced apoptosis of human melanoma is mediated by activation of c-Jun NH2-terminal kinase and inhibited by the mitogen-activated protein kinase extracellular signal-regulated kinase 1/2 pathway

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.226

7 January 2021

BRAFE600-associated senescence-like cell cycle arrest of human naevi

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.226

7 January 2021

Synergistic inhibition of human melanoma proliferation by combination treatment with B-Raf inhibitor BAY43-9006 and mTOR inhibitor Rapamycin

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.226

7 January 2021

Oncogene-induced cell senescence--halting on the road to cancer

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.226

7 January 2021

Lonafarnib in cancer therapy.

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.226

7 January 2021

X-ray and NMR structure of human Bcl-xL, an inhibitor of programmed cell death

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.226

7 January 2021

Decreased expression of Apaf-1 with progression of melanoma

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.226

7 January 2021

Progression of human cutaneous melanoma is associated with loss of expression of c-kit proto-oncogene receptor.

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.226

7 January 2021

Small molecule obatoclax (GX15-070) antagonizes MCL-1 and overcomes MCL-1-mediated resistance to apoptosis

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.226

7 January 2021

Notch and NOXA-related pathways in melanoma cells.

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.226

7 January 2021

Elimination of Mcl-1 is required for the initiation of apoptosis following ultraviolet irradiation

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.226

7 January 2021

Tumor cell-selective regulation of NOXA by c-MYC in response to proteasome inhibition.

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.226

7 January 2021

Mechanisms of hair graying: incomplete melanocyte stem cell maintenance in the niche

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.226

7 January 2021

An inhibitor of Bcl-2 family proteins induces regression of solid tumours

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.226

7 January 2021

Cytoplasmic and nuclear accumulation of beta-catenin is rarely caused by CTNNB1 exon 3 mutations in cutaneous malignant melanoma

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.226

7 January 2021

GSK-3beta inhibition enhances sorafenib-induced apoptosis in melanoma cell lines

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.226

7 January 2021

BRAF mutations are sufficient to promote nevi formation and cooperate with p53 in the genesis of melanoma.

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.226

7 January 2021

Coexpression of NRASQ61R and BRAFV600E in human melanoma cells activates senescence and increases susceptibility to cell-mediated cytotoxicity.

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.226

7 January 2021

High frequency of BRAF mutations in nevi

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.226

7 January 2021

Enhanced killing of melanoma cells by simultaneously targeting Mcl-1 and NOXA.

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.226

7 January 2021

Proteasome inhibitors trigger NOXA-mediated apoptosis in melanoma and myeloma cells

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.226

7 January 2021

Epigenetic control in the immune response

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.226

7 January 2021

Overcoming resistance to interferon-induced apoptosis of renal carcinoma and melanoma cells by DNA demethylation

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.226

7 January 2021

Frequent nuclear/cytoplasmic localization of beta-catenin without exon 3 mutations in malignant melanoma

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.226

7 January 2021

Structure and regulation of Kit protein-tyrosine kinase--the stem cell factor receptor

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.226

7 January 2021

Epigenetic events in malignant melanoma.

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.226

7 January 2021

Stabilization of beta-catenin by genetic defects in melanoma cell lines

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.226

7 January 2021

Two CD95 (APO-1/Fas) signaling pathways

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.226

7 January 2021

Identification of cells initiating human melanomas

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.226

7 January 2021

Genetic analysis of chemoresistance in primary murine lymphomas.

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.226

7 January 2021

Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.226

7 January 2021

Mutant V599EB-Raf regulates growth and vascular development of malignant melanoma tumors

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.226

7 January 2021

Both products of the mouse Ink4a/Arf locus suppress melanoma formation in vivo.

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.226

7 January 2021

Expression of activated Akt and PTEN in malignant melanomas: relationship with clinical outcome

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.226

7 January 2021

Farnesyl transferase inhibitor SCH66336 is cytostatic, pro-apoptotic and enhances chemosensitivity to cisplatin in melanoma cells

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.226

7 January 2021

Multiple signaling pathways must be targeted to overcome drug resistance in cell lines derived from melanoma metastases

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.226

7 January 2021

Inactivation of the apoptosis effector Apaf-1 in malignant melanoma

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.226

7 January 2021

Apoptosis and melanoma chemoresistance

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.226

7 January 2021

BRAF mutation predicts sensitivity to MEK inhibition

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.226

7 January 2021

Prevalence of p16 and CDK4 germline mutations in 48 melanoma-prone families in France. The French Familial Melanoma Study Group [published erratum appears in Hum Mol Genet 1998 May;7(5):941]

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.226

7 January 2021

Deregulated Akt3 activity promotes development of malignant melanoma

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.226

7 January 2021

Melanomas require HEDGEHOG-GLI signaling regulated by interactions between GLI1 and the RAS-MEK/AKT pathways.

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.226

7 January 2021

Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.226

7 January 2021

Significant impact of promoter hypermethylation and the 540 C>T polymorphism of CDKN2A in cutaneous melanoma of the vertical growth phase

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.226

7 January 2021

Waardenburg syndrome type 2 caused by mutations in the human microphthalmia (MITF) gene.

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.226

7 January 2021

Mcl-1 antisense therapy chemosensitizes human melanoma in a SCID mouse xenotransplantation model

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.226

7 January 2021

Could BRAF mutations in melanocytic lesions arise from DNA damage induced by ultraviolet radiation?

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.226

7 January 2021

Caspases: enemies within

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.226

7 January 2021

Management of cutaneous melanoma

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.226

7 January 2021

Genetic interaction between NRAS and BRAF mutations and PTEN/MMAC1 inactivation in melanoma

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.226

7 January 2021

Identification of PTEN/MMAC1 alterations in uncultured melanomas and melanoma cell lines

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.226

7 January 2021

Valproic acid induces apoptosis, p16INK4A upregulation and sensitization to chemotherapy in human melanoma cells

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.226

7 January 2021

Bcl-2 gene promotes haemopoietic cell survival and cooperates with c-myc to immortalize pre-B cells

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.226

7 January 2021

A novel BH3 mimetic reveals a mitogen-activated protein kinase-dependent mechanism of melanoma cell death controlled by p53 and reactive oxygen species.

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.226

7 January 2021

Virtually 100% of melanoma cell lines harbor alterations at the DNA level within CDKN2A, CDKN2B, or one of their downstream targets

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.226

7 January 2021

Apoptosis induction in human melanoma cells by inhibition of MEK is caspase-independent and mediated by the Bcl-2 family members PUMA, Bim, and Mcl-1.

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.226

7 January 2021

Microphthalamia-associated transcription factor: a critical regulator of pigment cell development and survival.

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.226

7 January 2021

Beta-catenin-induced melanoma growth requires the downstream target Microphthalmia-associated transcription factor

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.226

7 January 2021

Proapoptotic Bak is sequestered by Mcl-1 and Bcl-xL, but not Bcl-2, until displaced by BH3-only proteins

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.226

7 January 2021

BRAF and c-kit gene copy number in mutation-positive malignant melanoma

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.226

7 January 2021

Human malignant melanoma: detection of BRAF- and c-kit-activating mutations by high-resolution amplicon melting analysis

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.226

7 January 2021

Therapeutic window for melanoma treatment provided by selective effects of the proteasome on Bcl-2 proteins

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.226

7 January 2021

Multicenter Phase II trial of high-dose imatinib mesylate in metastatic melanoma: significant toxicity with no clinical efficacy

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.226

7 January 2021

Mutations of the BRAF gene in benign and malignant melanocytic lesions

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.226

7 January 2021

Specific protection against breast cancers by cyclin D1 ablation

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.226

7 January 2021

Differential regulation of Bax and Bak by anti-apoptotic Bcl-2 family proteins Bcl-B and Mcl-1.

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.226

7 January 2021

Nerve growth factor rescues pigment cells from ultraviolet-induced apoptosis by upregulating BCL-2 levels

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.226

7 January 2021

Activation of ERK1/2 protects melanoma cells from TRAIL-induced apoptosis by inhibiting Smac/DIABLO release from mitochondria

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.226

7 January 2021

ARF promotes MDM2 degradation and stabilizes p53: ARF-INK4a locus deletion impairs both the Rb and p53 tumor suppression pathways

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.226

7 January 2021

Epigenetic PTEN silencing in malignant melanomas without PTEN mutation

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.226

7 January 2021

Germline mutations in the p16INK4a binding domain of CDK4 in familial melanoma

1 reference

https://api.crossref.org/works/10.1038%2FJID.2008.226

7 January 2021

Identifiers

DOI

10.1038/JID.2008.226

1 reference

19 August 2017

1 reference